



MARYLAND MEDICAL CANNABIS COMMISSION

A Commission Resolution concerning

Review and Approval of Products Seeking an Exemption under COMAR 10.62.37.21

FOR the purpose of expediting the process for reviewing a product seeking an exemption from the Commission's edible cannabis regulations under COMAR 10.62.37.21; and generally relating to the pre-market review of medical cannabis products.

WHEREAS, The Health – General Article 13-3301, Annotated Code of Maryland and the Code of Maryland Regulations (COMAR) 10.62.37.21 authorize the Commission to exempt certain products from the definition of, and regulations governing edible cannabis products;

WHEREAS, The Commission adopted a Resolution on January 27, 2022, clarifying the regulatory requirements for a product to obtain an exemption under COMAR 10.62.37.21, including the type of certification that would comply with the “accredited third-party certification body in alternative pharmaceutical or dietary supplement certification approved by the Commission” under 10.62.37.21.C.(4);

WHEREAS, The Commission has reviewed and considered dozens of product exemption requests in accordance with the standards outlined in COMAR 10.62.37.21 and the Resolution adopted on January 27, 2022;

WHEREAS, Having reviewed and considered these product exemption requests, the Commission recognizes many of the submissions involve the same product dosage form and/or the products contain the same amount of THC per serving;

NOW THEREFORE BE IT RESOLVED, That the Commission hereby endorses and authorizes Commission staff to review and approve applications to exempt products from the edible cannabis regulations in the following limited circumstances:

1. The licensed processor has submitted, and the Commission has approved, a valid certification in Current Good Manufacturing Practices (cGMP) that complies with 21 CFR Part 111 or 21 CFR Part 210;
2. The product submitted is in a dosage form previously approved by the Commission; and
3. The product submitted contains a THC amount per serving and per package previously approved by the Commission.

The above resolution was adopted unanimously by the Commission members at the September 22, 2022, meeting of the Maryland Medical Cannabis Commission.



Tiffany D. Randolph, Esq., Chair

09/23/2022

Date